1. Myeloma UK. Myeloma – An Introduction. Disponibile all’indirizzo: . Ultimo accesso: maggio 2021.
  2. Myeloma UK. Infopack for newly diagnosed myeloma patients. Disponibile all’indirizzo: Ultimo accesso: maggio 2021.
  3. Durie GMB. Concise Review of the Disease and Treatment Options. International Myeloma Foundation. 2018;1-28. Disponibile all’indirizzo: . Ultimo accesso: maggio 2021.
  4. Kazandjian D, Langren O. A look back and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patients survival. Semin Oncol. 2016;43(6):682-689.
  5. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008 Mar 15;111(6):2962-72. doi: 10.1182/blood-2007-10-078022.
  6. ESMO/ACF Patient Guide Series 2017. What is Multiple Myeloma? Let us explain it to you. Disponibile all’indirizzo: . Ultimo accesso: maggio 2021.
  7. Moreau P et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv52-iv61.
  8. Cancer Research UK. Types of myeloma. Disponibile all’indirizzo: . Ultimo accesso: maggio 2021.
  9. Cancer Research Institute. Multiple Myeloma: Types of Treatment. Disponibile all’indirizzo: Pubblicato: luglio 2018. Ultimo accesso: maggio 2021.
  10. International Myeloma Foundation. What is multiple myeloma? Disponibile all’indirizzo: . Ultimo accesso: maggio 2021.
  11. Chim CS et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32(2):252-62.
  12. Nishida H. Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review. Cancers. 2021;13:2712. Disponibile all’indirizzo: .
  13. Mayo Clinic. Acute kidney failure. 2018;1-6. Disponibile all’indirizzo: . Ultimo accesso: maggio 2021.
  14. Thalidomide Celgene. Summary of Product Characteristics. Gennaio 2018.
  15. Sehgal K et al. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood. 2015;125:4042-51.
  16. Phaik Ju Teoh, Wee Joo Chng. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 2021 Apr;11(4):84.
  17. Zah E et al. T cells expressing cD19/CD20 bi-specific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res. 2016;4(6):498-508.
  18. Xiang Zhou et al. Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma. J Clin Med. 2020;9(7):2166.
  19. Cancer Research Institute. Multiple myeloma clinical trial targets. Disponibile all’indirizzo: 2018. Ultimo accesso: maggio 2021.
  20. Sondergeld P et al. Monoclonal antibodies in myeloma. Clin Adv Hematol Oncol. 2015;13(9):599-609.
  21. Costa F et al. Checkpoint inhibition in myeloma: opportunities and challenges. Front Immunol. 2018;9:2204.
  22. Revlimid. Summary of Product Characteristics. Gennaio 2017.
  23. Imnovid. Summary of Product Characteristics. Luglio 2018.
  24. National Cancer Institute. SEER Training Modules. Types of chemiotherapy drugs. Disponibile all’indirizzo: . Ultimo accesso: maggio 2021.
  25. Bendamustine Hydrochloride. Summary of Product Characteristics. Gennaio 2019.
  26. Melphalan. Disponibile all’indirizzo: . Ultimo accesso: maggio 2021.
  27. European Medicine Agency. Levact. Disponibile all’indirizzo: https://www.ema Ultimo accesso: maggio 2021.
  28. Cyclophosphamide. Summary of Product Characteristics. Giugno 2018.
  29. Melphalan. Summary of Product Characteristics. Marzo 2014.
  30. Myeloma Patients Europe. Panobinostat. Disponibile all’indirizzo: Ultimo accesso: maggio 2021.
  31. Empliciti. Summary of Product Characteristics. Ottobre 2019.
  32. Cho SF et al. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol . 2018;9:1821.
  33. Lonial S et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer. 2021 Nov 15;127(22):4198-4212.
  34. Al-Farsi K. Multiple myeloma: an update. Oman Med J.2013;28(1):3-11.
  35. Smith D, Yong K. Multiple myeloma. BMJ 2013;346:f3863.
  36. Vallet S et al. Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies. Pharmaceutics. 2018;10(4):202.
  37. Cömert M et al. Quality of life and supportive care in multiple myeloma. Turk J Haematol. 2013;30(3):234-46.
  38. Mortara L et al. Anti-cancer therapies employing IL-2 cytokine tumor targeting: contribution of innate, adaptive and immunosuppressive cells in the anti-tumor efficacy. Front Immunol. 2018;9:2905.
  39. Flavell L. NY-ESO TCR. Disponibile all’indirizzo: Ultimo accesso: maggio 2021.
  40. Melão A. Investigational cancer vaccine galinpepimut-S receives orphan drug status in EU for multiple myeloma. Disponibile all’indirizzo: Pubblicato: settembre 2018. Ultimo accesso: maggio 2021.
  41. Myeloma Patients Europe. Caring For Yourself. Disponibile all’indirizzo: Ultimo accesso: maggio 2021.
  42. American Society of Clinical Oncology. Managing stress. Disponibile all’indirizzo: Pubblicato: luglio 2019. Ultimo accesso: maggio 2021.
  43. Conner TS. Everyday creative activity as a path to flourish. J Positive Psychol. 2018;13(2):181-9. doi: 10.1080/17439760.2016.1257049.
  44. Arends J et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017 Feb;36(1):11. doi: 10.1016/j.clnu.2016.07.015.
  45. AIOM. Assistenza psico-sociale dei malati oncologici, 2019. .
  46. Associazione Italiana contro Leucemie, Linfomi e Mieloma (AIL). Mieloma ti sfido. Disponibile all’indirizzo: .
  47. de Vries M, Stiefel F. Psychotherapy in the Oncology Setting. Recent Results Cancer Res. 2018;210:145-61. doi: 10.1007/978-3-319-64310-6_9. PMID: 28924684.
  48. Istituto Toscano Tumori. Psiconcologia, Percorsi, strumenti, prospettive di ricerca. Disponibile all’indirizzo: .
  49. Lattanzi M. Psiconcologia: affrontare la malattia oncologica. State of Mind, 2015. Disponibile all’indirizzo:
  50. Okuyama T et al. Psychotherapy for depression among advanced, incurable cancer patients: A systematic review and meta-analysis. Cancer Treat Rev. 2017 May;56:16-27. doi: 10.1016/j.ctrv.2017.03.012. Epub 2017 Apr 11. PMID: 28453966.
  51. Portigliatti Pomeri A et al. EMDR in Cancer Patients: A Systematic Review. Front Psichol. 2021 Jan 18;11:590204. doi: 10.3389/fpsyg.2020.590204. PMID: 33536968; PMCID: PMC7847844.
  52. Yusufov M et al. Measures of Psychosocial Care Utilization in a National Sample of Cancer Patients. J Consult Clin Psychol. 2019;87(3):234-45. 0022-006X/19/$12.00. .
  53. Carlson LE. Mindfulness-based interventions for coping with cancer. Ann N Y Acad Sci. 2016 Jun;1373(1):5-12. doi: 10.1111/nyas.13029. Epub 2016 Mar 9. PMID: 26963792.
  54. Zhang MF et al. Effectiveness of Mindfulness-based Therapy for Reducing Anxiety and Depression in Patients With Cancer: A Meta-analysis. Medicine (Baltimore). 2015 Nov;94(45):e0897-0. doi: 10.1097/MD.0000000000000897. PMID: 26559246; PMCID: PMC4912240.
  55. Johnson E. Patient Power: Endless Benefits of Yoga for Cancer Patients, Myeloma Crowd. Disponibile all’indirizzo: .
  56. Megan M. Cancer Rehab and Exercise for the Patient with Multiple Myeloma. Aurora Health Care. Disponibile all’indirizzo: .
  57. Servadio M et al. Physical activity and health-related quality of life in multiple myeloma survivors: the PROFILES registry. BMJ Support Palliat Care. 2020 Dec;10(4):e35. doi: 10.1136/bmjspcare-2018-001755. Epub 2019 Jun 28. PMID: 31253733.
  58. Smith L et al. Multiple myeloma and physical activity: a scoping review. BMJ Open. 2015 Nov 27;5(11):e009576. doi: 10.1136/bmjopen-2015-009576. Erratum in: BMJ Open. 2016;6(2):e009576corr1. PMID: 26614625; PMCID: PMC4663409.
  59. Weill Cornell Medicine Myeloma Center. Staying Active and Safe with Multiple Myeloma. Disponibile all’indirizzo: .
  60. Maher K, de Vries K. An exploration of the lived experiences of individuals with relapsed multiple myeloma. Eur J Cancer Care (Engl). 2011 Mar;20(2):267-75. doi: 10.1111/j.1365-2354.2010.01234.x. Epub 2020 Oct 18. PMID: 20950368.
  61. American Society of Clinical Oncology. Caregivers taking care of themselves. Disponibile all’indirizzo: Pubblicato: settembre 2019. Ultimo accesso: maggio 2021.
  62. Monterosso L et al. Living With Multiple Myeloma: A Focus Group Study of Unmet Needs and Preferences for Survivorship Care. J Patient Exp. 2018;5(1):6-15. doi: 10.1177/2374373517715011.
  63. Stephens M et al. The work of living with a rare cancer: multiple myeloma. J Adv Nurs. 2014 Dec;70(12):2800-9. doi: 10.1111/jan.12430. Epub 2014 Apr 13. PMID: 24725097.
  64. Garza-Villareal EA et al. Music-Induced Analgesia in Chronic Pain Conditions: A Systematic Review and Meta-Analysis. Pain Physician. 2017 Nov;20(7):597-610.
  65. Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, Bandera EV, Hamilton KK, Grant B, McCullough M, Byers T, Gansler T. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012 Jul-Aug;62(4):243-74.
  66. (ultimo accesso 05/05/2023)
  67. Oben, B., Froyen, G., Maclachlan, K.H. et al. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nat Commun 12, 1861 (2021).